Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABAL.L Regulatory News (ABAL)

  • There is currently no data for ABAL

Pharmaceutical Contract Win

14 Jan 2009 07:00

RNS Number : 5695L
Imaginatik PLC
14 January 2009
 



14 January 2009

Imaginatik Plc

("Imaginatik" or the "Company")

Pharmaceutical Contract Win

Imaginatik plc (AIM: IMTK), a leading provider of cost reduction, process improvement and collaborative innovation software and processes, is pleased to announce it has secured an annual contract with one of the world's leading pharmaceutical companies.

The annual contract, for 5,000 seats, is further evidence of the Company's strong presence within the pharmaceutical industry with the new client joining the likes of Pfizer, Merck, Novartis and Solvay on Imaginatik's client list. Imaginatik now provides its collaborative software to six of the world's top pharmaceutical companies, assisting those companies in harnessing the knowledge of their thousands of employees to identify potential new products, areas of cost-reduction and process enhancements. 

Under the terms of the contract, Imaginatik will be implementing its core product, Idea Central, across a number of divisions within the client, including Research, Prescription Medicine and IT. Idea Central will play a key role in delivering process and product improvement within these divisions.

A spokesperson for the client commented, "In furthering our emphasis on Value through Innovation, Imaginatik's Idea Central provided a focal point for idea generation and sharing, streamlined our reviewing process, and served as a vehicle for ongoing communication. We found Imaginatik's software and services to be particularly effective."

Mark Turrell, CEO of Imaginatik plc commented, "We are delighted to see the investment placed on strengthening our sales team being rewarded with significant annual contract wins which add to our increasingly impressive recurring revenue figure. This contract also once again demonstrates the value of our collaborative software to the pharmaceutical industry and we are confident that this will continue to be an excellent vertical for Imaginatik going forward."

For further information please contact:

Imaginatik plc

Tel: 020 7917 2975

Mark Turrell, CEO / Shawn Taylor, CFO

WH Ireland Limited

Tel: 0121 265 6330

Tim Cofman / Katy Birkin

ICIS

Tel: 020 7651 8688

Caroline Evans-Jones / Mike Smith

About Imaginatik

Imaginatik is the leading provider of cost reduction, process improvement and collaborative innovation software and processes to the world's leading companies. More than 100 clients rely on Imaginatik's software, consulting and research to enable their best-of-breed innovation activities.

Named as a World Economic Forum Technology Pioneer for 2008 and a finalist for the IBM Lotus Awards 2008 in the Best Industry Solution category, Imaginatik's software and consulting services have helped clients discover significant sources of additional revenue, as well as tangible cost savings, process improvements and increased product pipeline. Imaginatik is also committed to developing strategic solutions in the field of innovation, working with academic institutions such as the London Business School and the Cass School of Business, London, as well as leading practitioners of corporate innovation.

For further information please visit www.imaginatik.com


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAUOOVRKORAAAR
Date   Source Headline
27th Sep 20187:30 amRNSSuspension - Imaginatik plc
26th Sep 20187:00 amRNSUpdate on potential equity investment
17th Sep 20187:00 amRNSUpdate on potential equity investment
11th Sep 201811:35 amRNSUpdate regarding Nominated Adviser
11th Sep 20187:00 amRNSFinal Results
4th Sep 20187:00 amRNSUpdate on potential equity investment
29th Aug 20189:22 amRNSHolding(s) in Company
28th Aug 20189:12 amRNSHolding(s) in Company
24th Aug 20183:39 pmRNSHolding(s) in Company
17th Aug 20183:40 pmRNSIssue of Equity
26th Jul 20187:00 amRNSNew Finance Agreement
25th Jul 20181:05 pmRNSStmnt re Share Price Movement
10th Jul 20184:56 pmRNSHolding(s) in Company
10th Jul 20189:48 amRNSHolding(s) in Company
10th Jul 20187:00 amRNSAppointment of CEO
3rd Jul 20185:45 pmRNSHolding(s) in Company
3rd Jul 20187:00 amRNSIssue of Equity
29th Jun 201810:46 amRNSResult of General Meeting and Total Voting Rights
22nd Jun 20187:00 amRNSContract Win
18th Jun 201812:59 pmRNSHolding(s) in Company
15th Jun 20187:00 amRNSRelease of mobile update to Innovation Central
14th Jun 20187:00 amRNSPosting of circular and notice of general meeting
5th Jun 20185:40 pmRNSHolding(s) in Company
5th Jun 20187:00 amRNSResult of strategic review and new funding
29th May 20187:00 amRNSUpdate on sales process and funding
1st May 20187:00 amRNSTrading Statement
21st Mar 20187:00 amRNSUpdate on strategic review and formal sale process
14th Feb 201812:38 pmRNSForm 8.3 - [Imaginatik plc]
12th Feb 20185:51 pmRNSForm 8.3 - Imaginatik plc
9th Feb 20185:50 pmRNSForm 8.3 - Imaginatik
9th Feb 20185:48 pmRNSForm 8.3 - Imaginatik
8th Feb 20183:36 pmRNSHolding(s) in Company
1st Feb 20183:04 pmRNSForm 8 (DD) - Imaginatik plc
1st Feb 201811:36 amRNSForm 8.3 - Imaginatik PLC
1st Feb 20187:00 amRNSForm 8 (OPD) - Imaginatik plc
1st Feb 20187:00 amRNSStrategic review including formal sale process
7th Dec 20177:00 amRNSHalf-year Report
29th Sep 20177:00 amRNSGrant of Options
27th Sep 20177:00 amRNSContract Win
20th Sep 20179:37 amRNSHolding(s) in Company
7th Sep 20175:50 pmRNSResult of AGM
15th Aug 20178:00 amRNSNotice of AGM
7th Aug 20177:00 amRNSFinal Results
10th Jul 201710:47 amRNSHolding(s) in Company
5th Jul 20174:32 pmRNSHolding(s) in Company
4th Jul 20179:51 amRNSHolding(s) in Company
4th Jul 20177:00 amRNSHolding(s) in Company
3rd Jul 201711:10 amRNSResult of Open Offer and Total Voting Rights
27th Jun 20177:00 amRNSResult of GM and Total Voting Rights
9th Jun 20171:04 pmRNSPlacing and Open Offer to raise up to £1.9 million

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.